2025
Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer. JAMA Network Open 2025, 8: e2514519. PMID: 40493365, PMCID: PMC12152704, DOI: 10.1001/jamanetworkopen.2025.14519.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerEGFR variationPD-L1ALK rearrangementCell lung cancerDriver alterationsMedical costsLung cancerCohort studyProgrammed cell death 1 ligand 1Cell death 1 ligand 1Biomarker statusMedian overall survivalRetrospective cohort studyLower medical costsOverall survivalTargeted therapyNon-smallPatient cohortMonthly medical costsFollow-upStudy cohortBiomarker testingAssociated with higher costsUse of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling.
Wang X, Long J, Rothen J, Huang S, Soulos P, Robinson T, Presley C, Goldberg S, Mamtani R, Ma S, Wang S, Kunst N, Dinan M, Gross C. Use of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling. Journal Of Clinical Oncology 2025, 43: 11155-11155. DOI: 10.1200/jco.2025.43.16_suppl.11155.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerTargeted therapyLung cancerTargetable alterationsGenomic profilingUsefulness of targeted therapyUS cancer clinicsFirst-line treatmentCohort of patientsClinico-genomic databaseNCCN GuidelinesIdentified patientsPatient populationFDA approvalTreatment selectionPatientsCancer clinicClinical guidelinesTherapyCancerLimited dataTT useFDA approval status
2023
Mutation-specific costs of advanced non-small cell lung cancer treatment.
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Mutation-specific costs of advanced non-small cell lung cancer treatment. JCO Oncology Practice 2023, 19: 14-14. DOI: 10.1200/op.2023.19.11_suppl.14.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerNon-small cell lung cancerMean medication costsActionable gene alterationsMedication costsFirst-year costsReference groupAdvanced non-small cell lung cancer (NSCLC) treatmentNon-small cell lung cancer (NSCLC) treatmentCell lung cancer treatmentGene alterationsBiomarker resultsFlatiron Health databasePD-L1 resultsTherapy prolongs survivalRetrospective cohort studyCell lung cancerBiomarker test resultsLung cancer treatmentCost-effectiveness analysisCohort studyNovel immunotherapiesOverall cohortProlong survivalTreatment options
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply